KR100693263B1 - 다중 투여형 에리트로포이에틴 제형 - Google Patents

다중 투여형 에리트로포이에틴 제형 Download PDF

Info

Publication number
KR100693263B1
KR100693263B1 KR1020027000944A KR20027000944A KR100693263B1 KR 100693263 B1 KR100693263 B1 KR 100693263B1 KR 1020027000944 A KR1020027000944 A KR 1020027000944A KR 20027000944 A KR20027000944 A KR 20027000944A KR 100693263 B1 KR100693263 B1 KR 100693263B1
Authority
KR
South Korea
Prior art keywords
delete delete
concentration
chloride
phenoxyethanol
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027000944A
Other languages
English (en)
Korean (ko)
Other versions
KR20020011143A (ko
Inventor
아테프 게이드
Original Assignee
아벤티스 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아벤티스 파마슈티칼스 인크. filed Critical 아벤티스 파마슈티칼스 인크.
Publication of KR20020011143A publication Critical patent/KR20020011143A/ko
Application granted granted Critical
Publication of KR100693263B1 publication Critical patent/KR100693263B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020027000944A 1999-07-22 2000-07-21 다중 투여형 에리트로포이에틴 제형 Expired - Fee Related KR100693263B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19821699P 1999-07-22 1999-07-22
US60/198,216 1999-07-22

Publications (2)

Publication Number Publication Date
KR20020011143A KR20020011143A (ko) 2002-02-07
KR100693263B1 true KR100693263B1 (ko) 2007-03-13

Family

ID=22732468

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027000944A Expired - Fee Related KR100693263B1 (ko) 1999-07-22 2000-07-21 다중 투여형 에리트로포이에틴 제형

Country Status (25)

Country Link
US (1) US7432360B2 (enExample)
EP (1) EP1200115B9 (enExample)
JP (1) JP2003517462A (enExample)
KR (1) KR100693263B1 (enExample)
CN (2) CN1371284A (enExample)
AT (1) ATE304863T1 (enExample)
AU (1) AU777397B2 (enExample)
BR (1) BR0012667A (enExample)
CA (1) CA2378945C (enExample)
CZ (1) CZ302750B6 (enExample)
DE (1) DE60022759T2 (enExample)
DK (1) DK1200115T3 (enExample)
EA (1) EA006220B1 (enExample)
EE (1) EE200200037A (enExample)
ES (1) ES2248110T3 (enExample)
HK (1) HK1050318A1 (enExample)
HR (1) HRP20020159B1 (enExample)
HU (1) HUP0202246A3 (enExample)
IL (2) IL147755A0 (enExample)
NO (1) NO20020303L (enExample)
NZ (1) NZ516735A (enExample)
PL (1) PL202945B1 (enExample)
RS (1) RS50355B (enExample)
WO (1) WO2001007075A2 (enExample)
ZA (1) ZA200200742B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU4602A (sh) 1999-07-22 2005-06-10 Aventis Pharmaceuticals Inc. Farmaceutske formulacije zaštićene od dejstva mikroorganizama
EP1525889A1 (en) 2000-05-15 2005-04-27 F. Hoffmann-La Roche Ag Liquid pharmaceutical composition containing an erythropoietin derivative
US7148211B2 (en) 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
CA2561222A1 (en) * 2004-03-26 2005-10-20 Janssen Pharmaceutica, N.V. Combination dosing regimen for erythropoietin
US7772182B2 (en) 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
BRPI0606784B1 (pt) * 2005-02-03 2018-07-31 Clariant Produkte (Deutschland) Gmbh Conservantes
JP2011116752A (ja) * 2009-10-29 2011-06-16 Jcr Pharmaceuticals Co Ltd エリスロポエチン含有水性液剤
KR101805087B1 (ko) * 2010-09-16 2017-12-05 주식회사 엘지화학 높은 방부력을 제공하는 오일 주사 제형
AU2016341241B9 (en) * 2015-10-22 2021-11-18 Iltoo Pharma Pharmaceutical compositions of IL-2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199992A1 (en) * 1985-03-28 1986-11-05 Eisai Co., Ltd. Adsorption-resistant peptide composition and use of benzalkonium or benzethonium chloride in the preparation thereof
US5045529A (en) * 1989-03-27 1991-09-03 Bionostics, Inc. Tonometric fluid for blood gas and co-oximetry instruments
EP0459795A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
US5503827A (en) * 1991-08-15 1996-04-02 Boehringer Mannheim Gmbh Process for the production of multi-dose pharmaceutical preparations containing isolated or recombinantly produced human protein for infusion or injection purposes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489837A (en) * 1968-07-11 1970-01-13 Leroy J Hyman Synergistic antiseptic composition consisting of 9-aminoacridine hydrochloride and benzethonium chloride
JPS6045849B2 (ja) 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
CA2050425A1 (en) * 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
JP2532025B2 (ja) * 1993-07-23 1996-09-11 株式会社林原生物化学研究所 新リンホカインｉｉｉを有効成分とする抗腫瘍作用を有するリンホカインの活性増強剤
US5968899A (en) * 1994-06-03 1999-10-19 Tsumura & Co. Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption
WO1997026004A1 (en) * 1996-01-19 1997-07-24 Eli Lilly And Company Obesity protein formulations
WO1998010785A1 (en) * 1996-09-13 1998-03-19 Advanced Medicine Research Institute Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
JPH1112193A (ja) * 1997-06-19 1999-01-19 Sankyo Co Ltd ヒトカルシトニン含有水溶液製剤
GB9726555D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199992A1 (en) * 1985-03-28 1986-11-05 Eisai Co., Ltd. Adsorption-resistant peptide composition and use of benzalkonium or benzethonium chloride in the preparation thereof
US5045529A (en) * 1989-03-27 1991-09-03 Bionostics, Inc. Tonometric fluid for blood gas and co-oximetry instruments
EP0459795A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
US5503827A (en) * 1991-08-15 1996-04-02 Boehringer Mannheim Gmbh Process for the production of multi-dose pharmaceutical preparations containing isolated or recombinantly produced human protein for infusion or injection purposes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EP 199992 A1. *
EP 459795 A1. *
US 5045529 A. *
US 5503827 A. *

Also Published As

Publication number Publication date
HUP0202246A2 (en) 2002-10-28
EE200200037A (et) 2003-04-15
NO20020303L (no) 2002-03-21
CN1371284A (zh) 2002-09-25
CA2378945A1 (en) 2001-02-01
DE60022759T2 (de) 2006-06-22
ATE304863T1 (de) 2005-10-15
ES2248110T3 (es) 2006-03-16
AU7137400A (en) 2001-02-13
IL147755A (en) 2009-11-18
HRP20020159A2 (en) 2003-06-30
CZ302750B6 (cs) 2011-10-19
IL147755A0 (en) 2002-08-14
EP1200115B1 (en) 2005-09-21
NO20020303D0 (no) 2002-01-21
EP1200115A2 (en) 2002-05-02
DE60022759D1 (de) 2006-02-02
CZ2002264A3 (cs) 2002-06-12
EA200200073A1 (ru) 2002-08-29
PL202945B1 (pl) 2009-08-31
HRP20020159B1 (en) 2007-08-31
YU4702A (sh) 2005-06-10
PL353569A1 (en) 2003-12-01
ZA200200742B (en) 2003-06-25
US20050267033A1 (en) 2005-12-01
RS50355B (sr) 2009-11-10
WO2001007075A3 (en) 2001-10-04
DK1200115T3 (da) 2006-01-16
HK1050318A1 (zh) 2003-06-20
AU777397B2 (en) 2004-10-14
KR20020011143A (ko) 2002-02-07
CN101091792A (zh) 2007-12-26
JP2003517462A (ja) 2003-05-27
NZ516735A (en) 2004-01-30
BR0012667A (pt) 2002-07-02
EP1200115B9 (en) 2006-01-18
US7432360B2 (en) 2008-10-07
HUP0202246A3 (en) 2010-01-28
WO2001007075A2 (en) 2001-02-01
EA006220B1 (ru) 2005-10-27
CA2378945C (en) 2010-02-23

Similar Documents

Publication Publication Date Title
KR100263282B1 (ko) 주입제 또는 주사제로 사용하기 위한 사람 단백질을 함유하는 방부된 약제의 제조방법
EP1232753B1 (en) Stable protein solution filled in a container made from a hydrophobic resin and method of stabilizing the same
AU750481B2 (en) Erythropoietin liposomal dispersion
EA008308B1 (ru) Жидкие стабилизированные белковые составы в фармацевтических контейнерах с покрытием
SK285650B6 (sk) Vodné prípravky moxifloxacínu a chloridu sodného,spôsob ich výroby a kombinovaný preparát
RU2242242C2 (ru) Препаративная форма стабильного водного раствора интерферона, способ ее приготовления и использования
KR100693263B1 (ko) 다중 투여형 에리트로포이에틴 제형
EP1166773B1 (en) Solution of N- O(p-pivaloyloxbenzenesulfonylamino)benzoyl glycine monosodium salt tetra-hydrate and drug product thereof
KR100514009B1 (ko) 1,2,4-벤조트리아진옥사이드제제
EP1524998B1 (en) Stable aqueous pharmaceutical composition comprising erythropoietin
EP1536822B1 (en) Stable pharmaceutical composition comprising erythropoietin
GB2125292A (en) Stable aqueous formulations of vinca alkaloids
HK1116419A (en) Multi-dose erythropoietin formulations
SK286990B6 (sk) Viacdávková kompozícia na báze erytropoetínu
MXPA02000804A (en) Multi dose erythropoietin formulations
Mercuriali et al. Albumin: Is It a Play-Maker, a Carrier or Both?

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20110209

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120306

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120306